SGMO — Sangamo Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $151.42m
- $121.81m
- $57.80m
Annual income statement for Sangamo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 118 | 111 | 111 | 176 | 57.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 248 | 294 | 313 | 450 | 162 |
| Operating Profit | -130 | -183 | -201 | -274 | -104 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -121 | -178 | -192 | -263 | -98.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -121 | -178 | -192 | -258 | -97.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -121 | -178 | -192 | -258 | -97.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -121 | -178 | -192 | -258 | -97.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.9 | -1.23 | -1.25 | -0.839 | -0.467 |